


Gene-Editing Therapies

MARKET & PIPELINE ANALYSIS



Market Insights




2023

First CRISPR/Cas9 Gene-Edited Therapy, **CASGEVY™**
for the Treatment of Sickle Cell Disease and Transfusion-Dependent Beta Thalassemia




Pipeline insights

Therapeutic Areas



555 Gene-edited Therapies
under development*

Delivery system**



Gene Editing Technology

